Alberto Del Rio - JoVE Visualize

Showing results (81-90 of 85) with videos related to

Pageof 9

Sort By:

You have reached the last page of results.This site can display upto 85 results.

Journal of Experimental & Clinical Cancer Research : CR|May 29, 2024

The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistancePaola Sanese, Katia De Marco, Martina Lepore Signorile, et al.

Signal Transduction and Targeted Therapy|June 30, 2025

Tailoring a novel colorectal cancer stem cell-targeted therapy by inhibiting the SMYD3/c-MYC axisMartina Lepore Signorile, Elisabetta Di Nicola, Giovanna Forte, et al.

Journal of Medicinal Chemistry|September 15, 2020

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4Robin A Fairhurst, Thomas Knoepfel, Nicole Buschmann, et al.

Human Gene Therapy|July 25, 2024

Improving the Assessment of Risk Factors Relevant to Potential Carcinogenicity of Gene Therapies: A Consensus ArticleJan C Klapwijk, Alberto Del Rio Espinola, Silvana Libertini, et al.

Toxicological Sciences : an Official Journal of the Society of Toxicology|October 24, 2012

Identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers for liver tumor promotionHarri Lempiäinen, Philippe Couttet, Federico Bolognani, et al.

Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:

Pageof 9

You have reached the last page of results.This site can display upto 85 results.

Journal of Experimental & Clinical Cancer Research : CR|May 29, 2024

The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistancePaola Sanese, Katia De Marco, Martina Lepore Signorile, et al.

Signal Transduction and Targeted Therapy|June 30, 2025

Tailoring a novel colorectal cancer stem cell-targeted therapy by inhibiting the SMYD3/c-MYC axisMartina Lepore Signorile, Elisabetta Di Nicola, Giovanna Forte, et al.

Journal of Medicinal Chemistry|September 15, 2020

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4Robin A Fairhurst, Thomas Knoepfel, Nicole Buschmann, et al.

Human Gene Therapy|July 25, 2024

Improving the Assessment of Risk Factors Relevant to Potential Carcinogenicity of Gene Therapies: A Consensus ArticleJan C Klapwijk, Alberto Del Rio Espinola, Silvana Libertini, et al.

Toxicological Sciences : an Official Journal of the Society of Toxicology|October 24, 2012

Identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers for liver tumor promotionHarri Lempiäinen, Philippe Couttet, Federico Bolognani, et al.

Pageof 9